Treatment of Myelofibrosis with JAK Inhibitors May Increase Risk for Aggressive Lymphoma

A study published in Blood showed that, based on a retrospective review of data, patients with myelofibrosis who have a pre-existing B-cell clone in their bone marrow and who are being treated with JAK1/2 inhibitors may be at an increased risk of developing aggressive B-cell lymphoma.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.